Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + apatinib + doxorubicin for first-line advanced soft tissue sarcoma
ChiCTR2600129579Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in soft tissue sarcoma (STS), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate (ORR). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2600129579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129579.